Rise in the prevalence rate of cancer & other genetic disorders, increasing preference in the personalized medicine, companies investments towards R&D, and growth of biotechnology and pharmaceutical industries, increase in private and public sector funding, rapid advancements in sequencing and gene editing technologies, applications in various drug discovery processes are some of the factors propelling the growth of the genome editing market. However, global gene editing market is hindered by stringent government regulations to approve gene mutation projects, ethical issues, unavailability of gene editing based therapeutics in the market and lack of awareness among people regarding the safety of genetic interventions.
A sample of this report is available upon request @
The gene editing market segmented based upon applications, technology, end-user, products, and region.
On the basis of technology, global genome editing market is segmented as:
Zinc Finger Nuclease (ZFN)
Clustered regularly interspaced short palindromic repeats (CRISPR)
Transcription activator-like effector nuclease (TALEN)
On the basis of application, global genome editing market is segmented as:
Cell Line Editing
Targeted gene mutation
Animal Genome Editing
Plant Genome Editing
On the basis of product type, global genome editing market is segmented as:
Instruments and Software
On the basis of end-user, Global Genome Editing Market is segmented as:
Clinical Research Organizations
To view TOC of this report is available upon request @
Biotechnology and pharmaceutical sectors dominate gene editing market due to its applications in drug discovery and therapeutics. Rise in usage of CRISPR and ZFN, companies are investing on innovative research for development of novel gene editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers and acquisitions, strategic or manufacturing activities are driving the growth of genome editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, specialty diagnostics and applied markets.In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.
Need more information about this report @
On the basis of Geographical regions, the genome editing market categorized into five regions:, Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The gene editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries. Emerging economies of Asia Pacific and Latin America are expected to show significant growth in the gene editing market due to an increase in the number of laboratories in these regions and development of existing ones for automation of various instrumentation systems, the expansion of leading genome editing companies and increased R&D spending.
Get access to full summary @
Some of the players in genome editing market are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.), Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc,(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S), and Transposagen Biopharmaceuticals, Inc.(U.S.)